rxstat › Classes › Antiepileptics

Antiepileptics: shortage status in Canada

10 of the 15 antiepileptics rxstat tracks are currently in shortage in Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.

Brivaracetam (Brivlera) Partial shortage 1 of 8 reported products affected Carbamazepine (Tegretol) Partial shortage 3 of 20 reported products affected · est. return Aug 21, 2026 Clonazepam (Rivotril) Partial shortage 5 of 21 reported products affected Lacosamide (Vimpat) Partial shortage 6 of 34 reported products affected · est. return Aug 10, 2026 Levetiracetam Partial shortage 13 of 48 reported products affected · est. return Sep 4, 2026 Oxcarbazepine (Trileptal) Partial shortage 3 of 8 reported products affected Phenytoin (Dilantin) Partial shortage 1 of 6 reported products affected · est. return Sep 1, 2026 Stiripentol (Diacomit) Partial shortage 1 of 1 reported products affected Topiramate (Topamax) Partial shortage 7 of 40 reported products affected Valproic Acid (Epival) Partial shortage 4 of 24 reported products affected · est. return Dec 30, 2026 Eslicarbazepine (Aptiom) Shortage anticipated 0 of 4 reported products affected Lamotrigine (Lamictal) No current shortage Perampanel (Fycompa) No current shortage Phenytoin (Dilantin-30) No current shortage Vigabatrin (Sabril) No current shortage

Guides: what to do when your medication is in shortage · how to read these statuses

Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.